Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.7K
Structure and Function of Platelets01:18

Structure and Function of Platelets

1.3K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

567
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
567
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

38
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
38

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum ferritin as a predictor of major adverse cardiovascular events in Takayasu arteritis: a two-center retrospective cohort study.

Clinical rheumatology·2026
Same author

Coronary artery vasculitis: an important differential diagnosis before coronary stenting.

European heart journal. Cardiovascular Imaging·2025
Same author

The role of granulocyte colony-stimulating factor in Takayasu arteritis.

Clinical rheumatology·2025
Same author

Risk factors and prognosis of depression in Takayasu arteritis patients.

Therapeutic advances in musculoskeletal disease·2024
Same author

CD8 cell-derived granzyme B may be a predictor for coronary artery involvement and MACE in Takayasu arteritis patients.

Clinical and experimental immunology·2024
Same author

Elevated serum 25-hydroxyvitamin D: a potential indicator of remission in Takayasu arteritis patients with normal ESR and CRP levels.

Clinical rheumatology·2024

Related Experiment Video

Updated: Jul 26, 2025

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

616

Platelet count as a potential predictor in refractory Takayasu arteritis.

Xuemei Shi1, Juan Du1, Taotao Li1

  • 1Department of Rheumatology and Immunology, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing, 100029, China.

Rheumatology International
|June 22, 2023
PubMed
Summary

Elevated platelet counts may predict refractory Takayasu arteritis (TAK). Higher platelet levels (PLT) were observed in refractory TAK patients, suggesting PLT as a potential indicator for closer monitoring and disease assessment.

Keywords:
Platelet countRefractory diseaseTakayasu arteritis

More Related Videos

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

964
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.1K

Related Experiment Videos

Last Updated: Jul 26, 2025

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

616
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

964
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.1K

Area of Science:

  • Rheumatology and Immunology
  • Hematology
  • Vascular Inflammation

Background:

  • Platelet parameters are recognized markers of disease severity across various conditions.
  • Takayasu arteritis (TAK) is a large-vessel vasculitis where disease severity and refractory disease course require better predictors.
  • Identifying reliable biomarkers for refractory TAK is crucial for timely intervention and improved patient outcomes.

Purpose of the Study:

  • To investigate the potential of platelet count (PLT) as a predictor of refractory Takayasu arteritis (TAK).
  • To identify associated risk factors and validate the predictive value of platelet count in TAK patients.

Main Methods:

  • Retrospective study design with a development data group (57 patients) and a validation data group (92 patients).
  • Analysis of platelet levels (PLT) in refractory versus non-refractory TAK patients.
  • Statistical analysis including risk factor identification, cut-off value determination, and survival analysis (cumulative incidence).

Main Results:

  • Refractory TAK patients exhibited significantly higher platelet counts (305.5 × 10⁹/L) compared to non-refractory patients (272.0 × 10⁹/L).
  • A platelet count cutoff of 296.5 × 10⁹/L was identified as a predictor of refractory TAK (OR 4.000, p=0.021).
  • Elevated PLT was associated with a higher proportion (55.6%) and increased cumulative incidence of refractory TAK over 1, 3, and 5 years (HR 2.106, p=0.035).

Conclusions:

  • Elevated platelet count is a statistically significant predictor of refractory Takayasu arteritis.
  • Clinicians should monitor platelet levels in TAK patients, with counts >296.5 × 10⁹/L warranting closer disease assessment and monitoring.
  • Platelet count serves as a valuable, accessible biomarker for identifying TAK patients at higher risk for a refractory disease course.